7CC Stock Overview
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Check-Cap Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.02 |
52 Week High | US$4.24 |
52 Week Low | US$1.15 |
Beta | 0.12 |
1 Month Change | -24.06% |
3 Month Change | 4.12% |
1 Year Change | 66.94% |
3 Year Change | -92.17% |
5 Year Change | -95.48% |
Change since IPO | -99.83% |
Recent News & Updates
Recent updates
Shareholder Returns
7CC | DE Medical Equipment | DE Market | |
---|---|---|---|
7D | 1.0% | 2.1% | 0.5% |
1Y | 66.9% | -8.4% | 1.3% |
Price Volatility
7CC volatility | |
---|---|
7CC Average Weekly Movement | 17.1% |
Medical Equipment Industry Average Movement | 4.7% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7CC's share price has been volatile over the past 3 months.
Volatility Over Time: 7CC's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2004 | 85 | Alex Ovadia | www.check-cap.com |
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient’s back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. Check-Cap Ltd.
Check-Cap Ltd. Fundamentals Summary
7CC fundamental statistics | |
---|---|
Market cap | €12.11m |
Earnings (TTM) | -€16.43m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs 7CC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
7CC income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$17.62m |
Earnings | -US$17.62m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -3.01 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did 7CC perform over the long term?
See historical performance and comparison